Post by icemandios on Apr 27, 2023 23:49:32 GMT
Ascendis Pharma Reports First Quarter 2023 Financial Results
April 27, 2023 at 4:01 PM EDT
PDF Version
• Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible
• 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded Access Program continues to enroll new patients
• SKYTROFA®* revenue reached €31.6 million in the first quarter of 2023; Ascendis expects full-year 2023 SKYTROFA revenue of €150 - €160 million
• Company to hold Oncology program update on Wednesday, May 31 in New York City
• Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
“Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the lives of many patients living with hypoparathyroidism and we are committed to working with regulatory authorities in the U.S. and EU to bring it to market as soon as possible,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We are managing our business to achieve our goal of reaching cash flow breakeven without the need for additional dilutive equity financing, supported by our first approved product, SKYTROFA, which is now accelerating to U.S. market value leadership. With advances across our portfolio and a focus on cost control, we remain on track to achieve Vision 3x3 to become a sustainable, profitable leading biopharma company.”
Select Highlights & Anticipated 2023 Milestones
TransCon hGH:
First quarter 2023 SKYTROFA revenue grew to €31.6 million, including a negative foreign currency impact of €1.4 million compared to the previous quarter.
April 27, 2023 at 4:01 PM EDT
PDF Version
• Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible
• 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded Access Program continues to enroll new patients
• SKYTROFA®* revenue reached €31.6 million in the first quarter of 2023; Ascendis expects full-year 2023 SKYTROFA revenue of €150 - €160 million
• Company to hold Oncology program update on Wednesday, May 31 in New York City
• Conference call today at 4:30 pm ET
COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
“Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the lives of many patients living with hypoparathyroidism and we are committed to working with regulatory authorities in the U.S. and EU to bring it to market as soon as possible,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We are managing our business to achieve our goal of reaching cash flow breakeven without the need for additional dilutive equity financing, supported by our first approved product, SKYTROFA, which is now accelerating to U.S. market value leadership. With advances across our portfolio and a focus on cost control, we remain on track to achieve Vision 3x3 to become a sustainable, profitable leading biopharma company.”
Select Highlights & Anticipated 2023 Milestones
TransCon hGH:
First quarter 2023 SKYTROFA revenue grew to €31.6 million, including a negative foreign currency impact of €1.4 million compared to the previous quarter.
